Follow
'Pancreatic ductal adenocarcinoma (PDA) remains one of the deadliest major cancers, contrasting a relatively low incidence rate1. The primary reasons for this are related to the difficulty with early detection and a lack of effective therapeutic options. A principal barrier to treatment of pancreatic cancer is the densely fibrotic tumor microenvironment, the high interstitial pressure of which acts to collapse blood vessels and impair the delivery of chemotherapy. This lack of functional vasculature leads to deregulated nutrient availability within the tumor, causing cancer cells to develop numerous metabolic adaptations to allow for proliferation under hypoxic and austere conditions'
